(PDF) Major Bleeding With Dabigatran and Rivaroxaban in

Major Bleeding With Dabigatran and Rivaroxaban in Patients With Atrial Fibrillation

Clinical and Applied Thrombosis/Hemostasis - United States

doi 10.1177/1076029614536606

Full Text

Abstract

Available in full text

Categories

Date

May 28, 2014

Authors

Gabriel V Fontaine

Scott M Stevens

Publisher

SAGE Publications

Related search

Pharmacoeconomic Analysis of Dabigatran in Patients With Atrial Fibrillation: Comparison With Rivaroxaban or Apixaban

Value in Health

Occupational Health

English

Characteristics, Management, and Outcomes of Patients With Atrial Fibrillation Experiencing a Major Bleeding Event While on Rivaroxaban

Clinical and Applied Thrombosis/Hemostasis

English

Risk Factors and Prevention of Dabigatran-Related Gastrointestinal Bleeding in Patients With Atrial Fibrillation

Journal of Arrhythmia

Cardiovascular Medicine

English

How to Use Dabigatran in Patients With Atrial Fibrillation

Rational Pharmacotherapy in Cardiology

Cardiovascular Medicine

English

Incidence of Major Bleeding Complication of Warfarin Therapy in Japanese Patients With Atrial Fibrillation

Circulation Journal

Cardiovascular Medicine

English

Mild Renal Disease Increases Major Bleeding in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Stenting

Thrombosis and Haemostasis

English

Prevention of Bleeding in Patients With Atrial Fibrillation Undergoing PCI

New England Journal of Medicine

English

Dabigatran Versus Warfarin in Patients With Atrial Fibrillation: An Analysis of Patients Undergoing Cardioversion

Cardiovascular Medicine

English

Assessing the Risk of Bleeding in Patients With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project

Circulation: Arrhythmia and Electrophysiology

Cardiovascular Medicine

English